Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Agilent Technologies

Thumbnail
November 20, 2019

Who will buy Qiagen?

The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.

Thumbnail
February 18, 2019

Auris acquisition could prompt more mega VC rounds

The J&J-Auris tie-up will yield a huge return for investors who went in big.

Article image
Vantage logo
July 25, 2018

Congenica aims to turn data into information

Sequencing data is all well and good, but what does it mean?

Vantage logo
January 25, 2016

2015 medtech approvals rocket

Vantage logo
October 12, 2015

Opdivo steals Keytruda’s thunder – again

Vantage logo
April 20, 2015

AACR – Keytruda set for lung cancer approval but restrictions unclear

Vantage logo
July 25, 2013

Medtech M&A on course for the worst year in a decade

Vantage logo
October 29, 2012

2012 sees largest pure medtech buy for seven years, but value of deals slump 27%

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.